2018, Image Interpretation, Imaging and Radiopharmaceuticals

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2018

Image Interpretation

Imaging

Radiopharmaceuticals

Blue Earth Diagnostics Announces Addition of POSLUMA (Flotufolastat F 18) Injection to NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer

Imaging Technology

JULY 28, 2023

It is the first and only FDA-approved, PSMA-targeted imaging agent developed with proprietary radiohybrid (rh) technology. Precision PET imaging with POSLUMA can help identify the location and extent of prostate cancer, providing clinically valuable information to guide patient management. POSLUMA was approved by the U.S.

Diagnostic

Diagnostic Clinic Radiopharmaceuticals Radiation

Additional Results of POSLUMA (Flotufolastat F 18) Performance in Newly Diagnosed, High-risk Prostate Cancer Patients Presented at ASTRO

Imaging Technology

OCTOBER 5, 2023

Specifically, this sub-group examined the performance of flotufolastat F 18 PET in newly diagnosed, high-risk prostate cancer patients who had negative results with conventional imaging. Kuo, MD, Ph.D. , Departments of Medical Imaging, Medicine, and Biomedical Engineering. Recently approved by the U.S. on behalf of Gary A.

Diagnose

Diagnose Diagnostic Disease Radiation

Diagnostic Imaging Brief

Blue Earth Diagnostics Announces Addition of POSLUMA (Flotufolastat F 18) Injection to NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer

Additional Results of POSLUMA (Flotufolastat F 18) Performance in Newly Diagnosed, High-risk Prostate Cancer Patients Presented at ASTRO

Stay Connected